DAVID K IMAGAWA, MD
Radiology at The City Dr, Orange, CA

License number
California 000000A44277
Category
Radiology
Type
Surgery
Address
Address 2
101 The City Dr SOUTH, Orange, CA 92868
PO Box 54708, Los Angeles, CA 90054
Phone
(714) 456-8978
(714) 456-6369

Organization information

See more information about DAVID K IMAGAWA at bizstanding.com

David K Imagawa MD

333 City Blvd W STE 1205, Orange, CA 92868

Categories:
General Surgeons
Phone:
(714) 456-3884 (Phone)

Professional information

David K Imagawa Photo 1

Dr. David K Imagawa, Orange CA - MD (Doctor of Medicine)

Specialties:
Transplant Surgery, Complex General Surgical Oncology
Address:
UCI Medical Physicians
333 City Blvd W STE 1205, Orange 92868
(714) 456-3884 (Phone)
Languages:
English, Vietnamese
Hospitals:
UCI Medical Physicians
333 City Blvd W STE 1205, Orange 92868
UC Irvine Health
101 The City Dr South, Orange 92868
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1986
University Of California Los Angeles
Graduated: 1987
Graduated: 1993
Graduated: 1995


David K Imagawa Photo 2

David K Imagawa, Orange CA

Specialties:
Surgeon
Address:
333 City Blvd W, Orange, CA 92868
101 The City Dr S, Orange, CA 92868
Board certifications:
American Board of Surgery Certification in Surgery


David Kevin Imagawa Photo 3

David Kevin Imagawa, Orange CA

Specialties:
Surgery, Surgical Oncology, Neurological Surgery, Neurology
Work:
Urgentcare Irvine Medical Center
101 The City Dr S, Orange, CA 92868
Education:
Johns Hopkins University (1986)


David Imagawa Photo 4

Use Of Perillyl Alcohol In Organ Transplantation

US Patent:
6133324, Oct 17, 2000
Filed:
May 6, 1999
Appl. No.:
9/305997
Inventors:
David K. Imagawa - Orange CA
Assignee:
The Regents of The University of California - Oakland CA
International Classification:
A61K 31045, A61K 31215, A61K 3800
US Classification:
514729
Abstract:
Perillyl alcohol and its monoterpene derivatives used alone or in combination with existing immunosuppressive agents, such as cyclosporine A and azathioprine, to provide methods and compositions which reduce allograft rejection in organ transplant patients.